PVX-410 Vaccine Safe, Immunogenic in Patients With Smoldering Multiple Myeloma

In a nonrandomized, phase 1/2b study, the PVX-410 vaccine demonstrated immunogenicity and safety as a monotherapy and in combination with lenalidomide. The most common adverse events reported were mild-to-moderate injection site reactions and constitutional symptoms, including chills, fatigue, myalgia, and pyrexia.

Oncology Learning Network